Adamis Pharmaceuticals Corporation Company Profile (NASDAQ:ADMP)

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation logoAdamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADMP
  • CUSIP:
Key Metrics:
  • Previous Close: $3.35
  • 50 Day Moving Average: $3.24
  • 200 Day Moving Average: $2.99
  • 52-Week Range: $21,584,000.00 - $2.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.45
  • P/E Growth: 0.00
  • Market Cap: $70.15M
  • Outstanding Shares: 21,584,000
  • Beta: -0.44
Profitability:
  • Return on Equity: -155.07%
  • Return on Assets: -98.68%
Debt:
  • Current Ratio: 1.22%
  • Quick Ratio: 1.10%
Additional Links:
Companies Related to Adamis Pharmaceuticals Corporation:

Analyst Ratings

Consensus Ratings for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.50 (130.77% upside)

Analysts' Ratings History for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Show:
DateFirmActionRatingPrice TargetDetails
1/25/2017Maxim GroupReiterated RatingBuy$10.00View Rating Details
1/24/2017B. RileyReiterated RatingBuy$5.00View Rating Details
5/29/2015MizuhoInitiated CoverageBuy$10.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Current Year EPS Consensus Estimate: $-1.48 EPS
Next Year EPS Consensus Estimate: $-0.73 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20161($0.21)($0.21)($0.21)
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.16)($0.16)($0.16)
Q3 20171($0.16)($0.16)($0.16)
Q4 20171($0.16)($0.16)($0.16)
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.11)($0.11)($0.11)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 13.74%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/2/2016David J MarguglioVPSell700$9.00$6,300.00View SEC Filing  
5/16/2016David J MarguglioSVPSell4,000$8.08$32,320.00View SEC Filing  
5/9/2016David J MarguglioSVPSell4,860$10.00$48,600.00View SEC Filing  
5/4/2016David J MarguglioSVPSell4,860$9.17$44,566.20View SEC Filing  
5/3/2016David J MarguglioSVPSell1,140$9.00$10,260.00View SEC Filing  
4/14/2016David J MarguglioSVPSell12,000$7.52$90,240.00View SEC Filing  
8/14/2015Robert B RothermelDirectorBuy7,000$3.33$23,310.00View SEC Filing  
4/20/2015David J MarguglioSVPSell200$5.00$1,000.00View SEC Filing  
4/14/2015David J MarguglioSVPSell2,200$5.01$11,022.00View SEC Filing  
3/4/2015David J MarguglioSVPSell11,800$7.09$83,662.00View SEC Filing  
3/2/2015David J MarguglioSVPSell7,000$6.45$45,150.00View SEC Filing  
2/13/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell12,076$6.41$77,407.16View SEC Filing  
2/12/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell38,000$6.40$243,200.00View SEC Filing  
2/3/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell30,000$6.75$202,500.00View SEC Filing  
1/5/2015David J MarguglioVPSell7,000$6.18$43,260.00View SEC Filing  
12/30/2014David J MarguglioSVPSell12,228$6.09$74,468.52View SEC Filing  
12/29/2014David J MarguglioVPSell772$6.00$4,632.00View SEC Filing  
12/12/2014David J MarguglioSVPSell4,000$5.18$20,720.00View SEC Filing  
9/2/2014William C DenbyDirectorBuy2,500$5.06$12,650.00View SEC Filing  
8/29/2014Robert B RothermelDirectorBuy5,500$4.03$22,165.00View SEC Filing  
6/2/2014David J MarguglioSVPSell4,000$5.56$22,240.00View SEC Filing  
8/14/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell7,015$0.57$3,998.55View SEC Filing  
8/7/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell40,000$0.56$22,400.00View SEC Filing  
8/2/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell67,960$0.57$38,737.20View SEC Filing  
7/30/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell10,328$0.56$5,783.68View SEC Filing  
7/26/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell95,000$0.56$53,200.00View SEC Filing  
7/23/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell141,224$0.57$80,497.68View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
DateHeadline
News IconStock Check: Reviewing the Numbers for Adamis Pharmaceuticals Corp (ADMP) - Davidson Register (NASDAQ:ADMP)
davidsonregister.com - February 25 at 4:24 AM
News IconStock Watch: Focusing in on Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - SKV News (NASDAQ:ADMP)
skvnews.com - February 25 at 4:24 AM
News IconNarrowing in on Chart Levels for Adamis Pharmaceuticals Corp (ADMP) - Baxter Review (NASDAQ:ADMP)
baxternewsreview.com - February 23 at 3:21 PM
News IconEquity Focus: Looking at Shares of Adamis Pharmaceuticals Corp (ADMP) - Rives Journal (NASDAQ:ADMP)
rivesjournal.com - February 22 at 3:22 PM
News IconMarket Review: Indicator Watch for Adamis Pharmaceuticals Corp (ADMP) - Davidson Register (NASDAQ:ADMP)
davidsonregister.com - February 21 at 3:37 PM
News IconShares in Review: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - SKV News (NASDAQ:ADMP)
skvnews.com - February 18 at 3:18 PM
News IconShares in Review: Watching the Levels for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Piedmont Register (NASDAQ:ADMP)
piedmontregister.com - February 17 at 3:29 PM
News IconMoody Stock Sees Increased Volatility Levels in Session: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Aiken Advocate (NASDAQ:ADMP)
aikenadvocate.com - February 16 at 3:23 PM
News IconInvestor Watch on Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Baxter Review (NASDAQ:ADMP)
baxternewsreview.com - February 16 at 6:43 AM
News IconStock Lower in Session: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Aiken Advocate (NASDAQ:ADMP)
aikenadvocate.com - February 14 at 3:34 PM
News IconVolatility Watch on Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - The Tribune (NASDAQ:ADMP)
lakecitytribune.com - January 31 at 8:25 PM
News IconTop Stock With Upside & Growth Potential: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Prospect Journal (NASDAQ:ADMP)
prospectjournal.com - January 31 at 3:24 PM
News IconMarket Focus – Tracking These Shares: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - The Tribune (NASDAQ:ADMP)
lakecitytribune.com - January 27 at 3:43 PM
barrons.com logoWhy Adamis Tops Impax Syringe at CVS Health - Barron's - Barron's (NASDAQ:ADMP)
www.barrons.com - January 23 at 8:24 PM
barrons.com logo[$$] Why Adamis Tops Impax Syringe at CVS Health (NASDAQ:ADMP)
www.barrons.com - January 23 at 3:21 PM
News Icon$ABBV FDA Nod For SGYP, Be All Ears For OTIC (NASDAQ:ADMP)
investorsbuz.com - January 21 at 3:19 PM
rttnews.com logoADMP Waiting To See If 3rd Time Is Charm, FDA Nod For SGYP, Be All Ears For OTIC (NASDAQ:ADMP)
www.rttnews.com - January 21 at 1:24 AM
us.rd.yahoo.com logo9:00 am Adamis Pharma announces that the FDA has accepted for review the Company's New Drug Application for its Epinephrine Pre-filled Syringe product candidate for the emergency treatment of anaphylaxis (NASDAQ:ADMP)
us.rd.yahoo.com - January 21 at 1:24 AM
nasdaq.com logoADMP Waiting To See If 3rd Time Is Charm, FDA Nod For SGYP, Be All Ears For OTIC - Nasdaq (NASDAQ:ADMP)
www.nasdaq.com - January 20 at 3:23 PM
News IconAmplified Volatility Spotted in Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Wall Street Beacon (NASDAQ:ADMP)
wsbeacon.com - January 19 at 8:36 PM
streetinsider.com logoAdamis Pharmaceuticals (ADMP) FDA Accepts Epinephrine Pre-Filled Syringe NDA Resubmission - StreetInsider.com (NASDAQ:ADMP)
www.streetinsider.com - January 19 at 3:34 PM
finance.yahoo.com logoAdamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA (NASDAQ:ADMP)
finance.yahoo.com - January 19 at 3:34 PM
News IconBrokers Add To Their Ratings On Adamis Pharmaceuticals Corporation (ADMP) - NewsDen (NASDAQ:ADMP)
newsden.net - January 18 at 3:49 PM
News IconAdamis Pharmaceuticals Corp ADMP Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ADMP)
www.bioportfolio.com - January 17 at 10:15 AM
News IconShort Interest: How Analysts Feel About Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) After Decrease in ... - Baxley Report (NASDAQ:ADMP)
baxleyreport.com - January 12 at 3:22 PM
News IconAre Institutions Jumping Ship on Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Wall Street Beacon (NASDAQ:ADMP)
wsbeacon.com - January 12 at 1:31 AM
biz.yahoo.com logoADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E (NASDAQ:ADMP)
biz.yahoo.com - January 11 at 3:28 PM
seekingalpha.com logoAdamis Pharmaceuticals: Beneficiary Of Mylan's EpiPen Fiasco? - Seeking Alpha (NASDAQ:ADMP)
seekingalpha.com - January 6 at 3:26 PM
News IconMy Watchlist for Friday, January 06 (NASDAQ:ADMP)
ac-investor.blogspot.com - January 5 at 8:40 PM
News IconStock Concentration on Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Wall Street Beacon (NASDAQ:ADMP)
wsbeacon.com - January 3 at 8:41 PM
News IconReady for an Upsurge? Analysts Chime in on Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Prospect Journal (NASDAQ:ADMP)
prospectjournal.com - January 3 at 8:07 AM
kcregister.com logoStocks Swings: QUALCOMM, Inc. (NASDAQ:QCOM), Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), Capital ... - KC Register (NASDAQ:ADMP)
www.kcregister.com - December 30 at 3:20 PM
News IconKnuckling Down on Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Prospect Journal (NASDAQ:ADMP)
prospectjournal.com - December 28 at 6:26 AM
News IconAre There Catalysts to Propel This Stock Forward: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Prospect Journal (NASDAQ:ADMP)
prospectjournal.com - December 26 at 3:18 PM
4-traders.com logoADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) Files An 8-K Other Events (NASDAQ:ADMP)
www.4-traders.com - December 23 at 8:51 PM
biz.yahoo.com logoADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Other Events (NASDAQ:ADMP)
biz.yahoo.com - December 23 at 8:51 PM
News IconAre Discerning Investors Interested in These Shares: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Prospect Journal (NASDAQ:ADMP)
prospectjournal.com - December 22 at 3:18 PM
News IconBoom or Bust? Is there any value in Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Prospect Journal (NASDAQ:ADMP)
prospectjournal.com - December 20 at 8:15 PM
News IconWatching the Numbers for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Liberty News (NASDAQ:ADMP)
libertynewsrecord.com - December 19 at 3:24 PM
News IconWatching the Numbers for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Highland Digest (NASDAQ:ADMP)
highlanddigest.com - December 17 at 8:22 PM
streetinsider.com logoAdamis Pharmaceuticals (ADMP) Re-Submits Epinephrine Pre-Filled Syringe NDA - StreetInsider.com (NASDAQ:ADMP)
www.streetinsider.com - December 16 at 3:26 PM
finance.yahoo.com logo9:03 am Adamis Pharma announces the resubmission of the Co's NDA to the FDA for its Epinephrine Pre-filled Syringe product candidate for the emergency treatment of anaphylaxis (NASDAQ:ADMP)
finance.yahoo.com - December 16 at 3:26 PM
publicnow.com logoAdamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA (NASDAQ:ADMP)
www.publicnow.com - December 16 at 3:26 PM
News IconNumbers in View on Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Business Daily Leader (NASDAQ:ADMP)
businessdailyleader.com - December 15 at 3:26 PM
insidermonkey.com logoIs VOXX International Corp (VOXX) A Good Stock To Buy? (NASDAQ:ADMP)
www.insidermonkey.com - December 15 at 3:26 PM
News IconBreakout Session Alert as Shares Pop BMO: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Prospect Journal (NASDAQ:ADMP)
prospectjournal.com - December 15 at 1:31 AM
News IconEnterprise Value Review for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - Liberty News (NASDAQ:ADMP)
libertynewsrecord.com - December 14 at 1:22 AM
News IconMy Watchlist for Wednesday, December 14 (NASDAQ:ADMP)
ac-investor.blogspot.com - December 13 at 8:22 PM
News IconEV in Focus on Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) - OIB News (NASDAQ:ADMP)
oibnews.com - December 12 at 8:26 PM
News IconAdamis Pharmaceuticals Corporation (ADMP) Valuation According To Analysts - UK Market News (NASDAQ:ADMP)
www.ukmarketnews.co.uk - December 9 at 8:25 PM

Social

What is Adamis Pharmaceuticals Corporation's stock symbol?

Adamis Pharmaceuticals Corporation trades on the NASDAQ under the ticker symbol "ADMP."

Where is Adamis Pharmaceuticals Corporation's stock going? Where will Adamis Pharmaceuticals Corporation's stock price be in 2017?

2 brokerages have issued 12 month price targets for Adamis Pharmaceuticals Corporation's shares. Their forecasts range from $5.00 to $10.00. On average, they expect Adamis Pharmaceuticals Corporation's stock price to reach $7.50 in the next year.

What are analysts saying about Adamis Pharmaceuticals Corporation stock?

Here are some recent quotes from research analysts about Adamis Pharmaceuticals Corporation stock:

  • According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (2/21/2017)

  • Maxim Group analysts commented, "While we are awaiting Tcelna POC data in SPMS (secondary progressive multiple sclerosis) this fall (early 4Q), we note that Novartis just announced that its drug BAF312 (siponimod) met the primary endpoint of improvement in time to 3-month confirmed disability progression" in the same indication (SPMS) in a pivotal phase III study (EXPAND")." (8/29/2016)

Who owns Adamis Pharmaceuticals Corporation stock?

Adamis Pharmaceuticals Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include Sabby Healthcare Master Fund, Ltd (4.99%), Bard Associates Inc. (0.72%) and Sterling Global Strategies LLC (0.19%). Company insiders that own Adamis Pharmaceuticals Corporation stock include David J Marguglio and Robert B Rothermel.

Who sold Adamis Pharmaceuticals Corporation stock? Who is selling Adamis Pharmaceuticals Corporation stock?

Adamis Pharmaceuticals Corporation's stock was sold by a variety of institutional investors in the last quarter, including Bard Associates Inc..

Who bought Adamis Pharmaceuticals Corporation stock? Who is buying Adamis Pharmaceuticals Corporation stock?

Adamis Pharmaceuticals Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Sterling Global Strategies LLC.

How do I buy Adamis Pharmaceuticals Corporation stock?

Shares of Adamis Pharmaceuticals Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Adamis Pharmaceuticals Corporation stock cost?

One share of Adamis Pharmaceuticals Corporation stock can currently be purchased for approximately $3.25.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Earnings History Chart

Earnings by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Dividend History Chart

Dividend Payments by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Last Updated on 2/26/2017 by MarketBeat.com Staff